- Home
- BCTX vs GELS Comparison
BCTX vs GELS Comparison
Compare BCTX & GELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- GELS
- Stock Information
- Founded
- BCTX 2014
- GELS 2018
- Country
- BCTX Canada
- GELS Australia
- Employees
- BCTX N/A
- GELS N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- GELS
- Sector
- BCTX Health Care
- GELS
- Exchange
- BCTX Nasdaq
- GELS NYSE
- Market Cap
- BCTX 16.1M
- GELS 8.7M
- IPO Year
- BCTX N/A
- GELS 2024
- Fundamental
- Price
- BCTX $3.18
- GELS $1.48
- Analyst Decision
- BCTX Strong Buy
- GELS
- Analyst Count
- BCTX 1
- GELS 0
- Target Price
- BCTX $32.00
- GELS N/A
- AVG Volume (30 Days)
- BCTX 3.7M
- GELS 4.7M
- Earning Date
- BCTX 06-13-2025
- GELS 02-15-2025
- Dividend Yield
- BCTX N/A
- GELS N/A
- EPS Growth
- BCTX N/A
- GELS N/A
- EPS
- BCTX N/A
- GELS N/A
- Revenue
- BCTX N/A
- GELS $95,618.00
- Revenue This Year
- BCTX N/A
- GELS N/A
- Revenue Next Year
- BCTX N/A
- GELS N/A
- P/E Ratio
- BCTX N/A
- GELS N/A
- Revenue Growth
- BCTX N/A
- GELS N/A
- 52 Week Low
- BCTX $0.35
- GELS $0.77
- 52 Week High
- BCTX $9.82
- GELS $5.50
- Technical
- Relative Strength Index (RSI)
- BCTX 37.13
- GELS N/A
- Support Level
- BCTX $4.04
- GELS N/A
- Resistance Level
- BCTX $9.82
- GELS N/A
- Average True Range (ATR)
- BCTX 0.75
- GELS 0.00
- MACD
- BCTX -0.22
- GELS 0.00
- Stochastic Oscillator
- BCTX 1.34
- GELS 0.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About GELS GELTEQ LIMITED
Gelteq Ltd is a clinical and science-based company that is focused on developing and commercializing white-label gel-based delivery solutions to preserve the simplicity, accessibility and efficacy of oral delivery without the impediments traditionally associated with other oral delivery methods, with prescription drugs, nutraceuticals, pet care, and other products. It is engaged in the development and testing of a gel-based delivery system for humans and pets. Its principal products are edible gels.